News

2022-06-30| Annual General Meeting in Vironova Medical AB

Vironova Medical AB (publ), 559008-5303 invite shareholders to the Annual General Meeting on the 30th of June 2022. The meeting will be held online only.

We need your registration by the 29th of June. You register via regular mail, so be sure to send your registration for the postal services to get it to us in time.

Please see the following documents for registration and further information:

Kallelse årsstämma 2022

Anmälan och formulär för röstning

Fullmaktsformulär årsstämma 2022

It is possible to vote online using bank-ID:
Register and pre-vote online

2021-06-30| Stämmokommuniké från årsstämman i Vironova Medical AB (publ)

Vid årsstämman i Vironova Medical AB (publ) den 30 juni 2021 fattades följande beslut

Stämman genomfördes enligt 20 och 22 §§ lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor, innebärande att aktieägarna fått utöva sin rösträtt vid stämman endast genom att rösta på förhand, s.k. poströstning.

Fastställande av årsbokslut och ansvarsfrihet
Årsstämman beslutade att fastställa resultat- och balansräkning för bolaget och koncernen för verksamhetsåret 2020. Årsstämman beslutade även om ansvarsfrihet för styrelseledamöterna och verkställande direktören.

Beslut om resultatdisposition
Årsstämman beslutade att bolagets resultat balanseras i ny räkning, och att någon utdelning således inte lämnas.

Val av styrelse och revisorer samt arvode till styrelsen och revisorerna
Till ordinarie ledamöter för tiden intill nästa årsstämma valdes Anders Milton, Mohamed Homman Loudiye, Alf Sollevi, Ulf Säther, Jan Bergman samt Mats Persson (samtliga omval) samt till styrelsesuppleanter valdes Maria Homman Loudiye (omval) och Claes Thurell (nyval). Till ordförande i styrelsen utsågs Anders Milton (omval).

Till revisor valdes Mazars AB med Johan Tilander som huvudansvarig revisor (omval).

Stämman beslutade att styrelsearvode ska utgå med 100 000 kr till ordföranden samt 50 000 kr till var och en av de stämmovalda ledamöterna som inte är anställda i bolaget. Arvode till revisorn ska utgå enligt godkänd räkning i enlighet med sedvanliga debiteringsnormer.

Emissionsbemyndigande
Stämman bemyndigade styrelsen att för tiden intill nästa årsstämma vid ett eller flera tillfällen fatta beslut om nyemission av aktier och/eller emission av konvertibler och/eller teckningsoptioner med eller utan företrädesrätt för bolagets aktieägare i enlighet med styrelsens förslag.

Kvittningsemission
Stämman beslutade i enlighet med styrelsens förslag om emission av högst 2 422 978 B-aktier till vissa fordringshavare i bolaget med rätt för tecknarna att betala för tecknade aktier genom kvittning av fordringar.

Samtliga beslut vid stämman fattades enhälligt.

Vironova Medical AB (publ)

Styrelsen

2021-06-30| Annual General Meeting in Vironova Medical AB

Vironova Medical AB (publ), 559008-5303 invites shareholders to the Annual General Meeting at the 30th of June 2021. The meeting will take place online only.

We need your registration for the meeting by the 29th of June. You register via regular mail, so be sure to send your registration for the postal services to get it to us in time.

Please view the following documents for registration and further information:

Kallelse bolagsstämma 2021
Anmälan och formulär för poströstning
Fullmaktsformulär

Register and pre-vote online:

Scrive

2020-12-23| Development of Vironova Medical´s SARS-CoV2 antiviral drugs

Vironova Medical AB are developing a novel class of antiviral drugs against covid-19/SARS-CoV-2, first evaluated in vitro against SARS-CoV-2 virus at the University of Melbourne in Australia in March 2020. The results showed good inhibition of the virus. Two independent international laboratories, The National Institute of Health (NIH) in the US and Commonwealth Scientific and Industrial Research Organisation in Australia (CSIRO), have since evaluated and confirmed the antiviral effect of Vironova Medical’s antiviral drugs in human cells.

A new patent application for this class of antiviral drugs for the indication of covid-19/SARS-CoV-2 was filed on the 9th of April 2020 (application no. EP20169129.2) by Vironova Medical.

Vironova Medical AB´s antiviral drugs were selected for a joint screening program for SARS-CoV-2 antivirals between CSIRO, the University of Melbourne, and the Royal Melbourne Hospital in April this year. A human lung model was used for the evaluation providing more factual data true to the virus disease in humans. Vironova Medical AB was invited, based on these promising results, to submit the antiviral drugs to The National Institute of Health in the US for evaluation in May. The NIH have confirmed the antiviral effect against SARS-CoV-2 in human cells.

In summary, two independent international laboratories (NIH and CSIRO) have evaluated and confirmed antiviral effect of Vironova Medical’s novel class of antiviral drugs in human cells. Research and development of these antiviral drugs continue in collaboration with the NIH.

As there is an enormous concern for the safety of multiple continents worldwide it is critical that accelerated development of these antiviral drugs is prioritized for the urgent need of alternative treatments for the pandemic SARS-CoV-2.

Vironova Medical AB are excited about these results and we see the great potential in this novel class of antiviral drugs, and we are ready to contribute what we can to help with the efforts against this virus.

To give you a hands on view of Vironova Medical’s contribution and expectations, we give the word to Vironova Medical´s Senior Scientist Ngarita Kingi, and Chief Scientific Officer Eva O´Keeffe.

Ngarita Kingi

Ngarita Kingi, M.Sc.
Senior Scientist
Vironova Medical AB

Eva O´Keeffe

Eva O´Keeffe, Ph.D.
Chief Scientific Officer
Vironova Medical AB

What is the next step?
We will continue with preclinical development, which is the stage before human testing or clinical trials can begin, to assess the safety profile of the drug along with other properties. Testing and development of these antiviral drugs continue in collaboration with the NIH.

When could a drug be on the market?
Preclinical development typically takes 1-2 years from where we are at now. If successful, clinical trials can start which run for 3-5 years. Vironova Medical is looking for a commercial partner to develop this drug together with, that could accelerate the process further.

Why do we need antiviral drugs if vaccines are available?
Vaccines are very important in combating a disease since they prevent infection in uninfected individuals by stimulating our immune system to recognize the virus. However, if a person has been infected with the virus, a vaccine will not help. Instead, you can be treated with an antiviral drug, that targets the virus itself. Sometimes vaccines do not work, mutations in the virus is one reason. Therefore, vaccines and antiviral drugs complement each other, and both are needed.

2020-06-30| Annual General Meeting in Vironova Medical AB

The shareholders of Vironova Medical AB (publ), 559008-5303, are hereby invited to the Annual General Meeting at 14:00 on the 30th of June 2019 at Vironova Medical’s premises, Gävlegatan 22, 113 30 Stockholm.

To register please visit:

https://www.vironova.com/registration-for-annual-meeting-2020-in-vironova-medical-ab

2019-08-28| Options X for the control of Influenza

Vironova Medical will be at the ISIRV conference Options X for the control of Influenza

Singapore 28 August-1 September

https://2019.isirv.org

 

2019-06-17| XVIII International Conference on Heterocycles in Bioorganic chemisty

Meet us in Ghent on the 17th-20th of June for the XVIII International Conference on Heterocycles in Bioorganic chemisty. Vironova Medical is the main sponsor of the event. Our Senior Scientist and Chemist Ngarita Kingi will give an oral presentation with the title:

Thionations Using a P4S10-Pyridine Complex.

2017-08-25| Vironova Medical AB was nominated to The Rising Star Award at SALSS

Vironova Medical was invited to participate in the renowned Swedish American Life Science Summit SALSS, an annual meeting that brings together scientists, entrepreneurs and investors with the aim is to build strategic and collaborative relationships between academia, industry and fundings.

2015-05-06| Vironova AB (publ) granted new US-patent for an anti-herpes compound.

Vironova Medical AB announces the approval of a new US-patent application. The patent cover topical administration against herpes with B-220 compound in U.S. (US2013310392). The approval enables Vironova to further develop a pharmaceutical formulation for topical administration against herpes simplex virus comprising of the B-220 compound.

2015-04-01| Vironova AB (publ) granted US patent for a Thionation reagent.

Vironova AB, a leading Nano-Characterization technology and software company announced the approval of a new patent application. The US Patent Office (USPTO) has granted Vironova a patent for a Thionation reagent (no 13/936423). Based on this innovation, Vironova continues to develop the technology for the US market where a number of chemical and pharmaceutical companies are stationed.